Pages that link to "Q46863365"
Jump to navigation
Jump to search
The following pages link to Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial (Q46863365):
Displaying 50 items.
- Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer (Q27015786) (← links)
- First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study (Q33378383) (← links)
- Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. (Q33397403) (← links)
- Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer. (Q33440396) (← links)
- Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer (Q33795052) (← links)
- Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel (Q34464827) (← links)
- Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck. (Q34623415) (← links)
- Pemetrexed for the treatment of non-small-cell lung cancer (Q35003631) (← links)
- Treatment of advanced non small cell lung cancer (Q35667817) (← links)
- Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose (Q35674153) (← links)
- Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis (Q36040002) (← links)
- The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update (Q36142491) (← links)
- Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines (Q36412597) (← links)
- Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party (Q36609433) (← links)
- Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma (Q36615597) (← links)
- Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study (Q36636822) (← links)
- Second-line Therapy for advanced non-small-cell lung cancer (Q36718606) (← links)
- Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics (Q36822393) (← links)
- ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin (Q36893674) (← links)
- Weekly low-dose docetaxel for salvage chemotherapy in pretreated elderly or poor performance status patients with non-small cell lung cancer (Q37030260) (← links)
- Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis (Q37108127) (← links)
- The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis (Q37135295) (← links)
- Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients (Q37205484) (← links)
- Docetaxel in the treatment of advanced non-small-cell lung cancer. (Q37242661) (← links)
- New avenues for second-line treatment of metastatic non-small-cell lung cancer (Q37357304) (← links)
- A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced non-small cell lung cancer (Q37620539) (← links)
- Refining the treatment of advanced nonsmall cell lung cancer. (Q37645169) (← links)
- Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. (Q37732287) (← links)
- Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All (Q37788430) (← links)
- Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy? (Q37797818) (← links)
- Second-line treatment options in advanced non-small cell lung cancer (Q37937879) (← links)
- Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors? (Q37945643) (← links)
- Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. (Q37957744) (← links)
- Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer (Q38258744) (← links)
- Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis (Q39139831) (← links)
- Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel (Q40521965) (← links)
- Daily oral administration of low-dose methotrexate has greater antirheumatic effects in collagen-induced arthritis rats (Q41552289) (← links)
- Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer (Q42984481) (← links)
- Weekly docetaxel and cisplatin plus fluorouracil as a preoperative treatment for gastric cancer patients with synchronous multiple hepatic metastases: a pilot study (Q43228285) (← links)
- Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor (Q45435712) (← links)
- A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer (Q46991010) (← links)
- A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum‐sensitive ovarian cancer (Q48549299) (← links)
- A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer (Q51028375) (← links)
- Low-Dose Weekly Docetaxel Is as Tolerable as Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer (Q51043526) (← links)
- Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance (Q51051494) (← links)
- Chemotherapy for Advanced Non-small Cell Lung Cancer. (Q52853807) (← links)
- Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. (Q53065761) (← links)
- Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer. (Q53567790) (← links)
- Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. (Q53578578) (← links)
- A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. (Q54645262) (← links)